Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Keith Wheatley is active.

Publication


Featured researches published by Keith Wheatley.


Archive | 2006

hTERT expression in AML is heterogeneous and is of likely prognostic significance

N. E. Jordanides; W. N. Keith; Robert Kerrin Hills; Keith Wheatley; Quang T. Luong; Alan Kenneth Burnett; T. L. Holyoake; M. W. Drummond

Molecular events in AML (e.g. Flt3-ITD) may be exploited as nprognostic indicators or therapeutic targets. The cancer- and stem/ nprogenitor cell-related enzyme telomerase is central to maintaining nthe immortal phenotype. We investigated whether levels of ntelomerase expression are of prognostic value in AML. Following nvalidation of the assay in a range of telomerase positive and negative ncell lines and tissues, 300 samples of archived peripheral blood MNC nRNA (MRC AML12 study) were analysed blindly by Q-PCR (Light- nCycler) for hTERT (the catalytic component of telomerase). Internal nQA utilised Q-PCR for the control gene PBGD. Only samples ngenerating 4103 PBGD transcripts were analysed. Results were nexpressed as hTERT/PBGD transcripts (%) and as either hTERT npositive or negative, or high, intermediate or low (43.2%, 40.7o n3.2, o0.7, respectively, according to levels detected in normal nCD341 PBSC and PBL MNC, median of 3.2% and 0.7%, respectively) nto facilitate statistical analysis. 1169 samples were analysed, with nhTERT transcripts undetectable in 75 (hTERT range 0–255.9%, nmedian 0.17%, mean 4.3%). When analysed on an hTERT-positive or nnegative basis, there was no correlation between hTERT levels and ncytogenetic risk group, FAB subgroups, white cell count or age. nUsing multivariate regression analysis, adjusted for the known nprognostic factors (as previous, plus performance status), there was nno evidence of differences in CR rate (OR 1.14, 95%CI 0.43–3.02, np50.8), but borderline evidence of worse overall survival (OS) and ndisease-free survival (DFS) among hTERT positive patients (5 year nOS: 39% vs 53% HR 1.54 (95%CI 0.97–2.45), p50.07; 5 year DFS: 42% nvs 54% HR 1.62 (95%CI 0.96–2.74), p50.07). Classifying hTERT as nhigh, intermediate or low, 5 year OS was 34%, 50% and 47% (p50.5 nfor trend). hTERT expression in AML is heterogeneous and may be nof prognostic significance. Larger studies are required to investigate nfurther these findings.


Blood | 2004

Genetic variation in XPD predicts treatment outcome and risk of acute myeloid leukemia following chemotherapy

James M. Allan; Alexandra G. Smith; Keith Wheatley; Robert Kerrin Hills; Lois B. Travis; Deirdre A. Hill; David Swirsky; Gareth J. Morgan; Christopher P. Wild


Blood | 2003

Cytogenetics of childhood AML from UK medical research council treatment trials, AML10 & 12.

Christine J. Harrison; Anthony V. Moorman; Robert Kerrin Hills; Ian M. Hann; David Grimwade; David Webb; Richard L. Stevens; Keith Wheatley; Brenda Gibson


Archive | 2013

randomized trial G-CSF and ATRA are not beneficial: results of the MRC AML-HR chemotherapy in high-risk acute myeloid leukemia, and addition of Fludarabine and cytosine are less effective than standard ADE

Donald Milligan; Keith Wheatley; Timothy Littlewood; Jenny I. O. Craig; Alan K. Burnett


Archive | 2013

Retinoic Acid: Result of the Randomized MRC Trial All-Trans Predict Prognosis in Acute Promyelocytic Leukemia Treated With Presenting White Blood Cell Count and Kinetics of Molecular Remission

Alan K. Burnett; D. Grimwade; Ellen Solomon; Keith Wheatley; Anthony H. Goldstone


Archive | 2013

tandem duplications in patients with acute myeloid leukemia and have a significantly more favorable prognosis than FLT3 internal FLT3 tyrosine kinase domain mutations are biologically distinct from

Adam J. Mead; David C. Linch; Robert Kerrin Hills; Keith Wheatley; Alan K. Burnett; E Rosemary


Archive | 2013

myeloid leukemia following chemotherapy Genetic variation in XPD predicts treatment outcome and risk of acute

David Swirsky; Gareth J. Morgan; Christopher P. Wild; James M. Allan; Alexandra G. Smith; Keith Wheatley; Robert Kerrin Hills; Lois B. Travis; Deirdre A. Hill


Archive | 2010

older patients: the results of the United Kingdom Medical Research Council Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in

Kay Wallace; Anthony H. Goldstone; Alan K. Burnett; Keith Wheatley; Alastair G. Smith; R. Michael Hutchinson; Sulin Pang


Archive | 2010

myeloid leukemia following chemotherapy predicts treatment outcome and risk of acute XPD Genetic variation in

David Swirsky; Gareth J. Morgan; Christopher P. Wild; James M. Allan; Alex Smith; Keith Wheatley; Robert Kerrin Hills; Lois B. Travis; Deirdre A. Hill


Archive | 2010

the Medical Research Council's 10th AML Trial (MRC AML10) in Children and Younger Adults With Acute Myeloid Leukemia. Results of Randomized Comparison of DAT Versus ADE as Induction Chemotherapy

Alan K. Burnett; Ian M. Hann; Richard F. Stevens; Anthony H. Goldstone; John Rees; Keith Wheatley

Collaboration


Dive into the Keith Wheatley's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Alan K. Burnett

Roswell Park Cancer Institute

View shared research outputs
Top Co-Authors

Avatar

Deirdre A. Hill

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Gareth J. Morgan

Leeds Teaching Hospitals NHS Trust

View shared research outputs
Top Co-Authors

Avatar

Ian M. Hann

Great Ormond Street Hospital

View shared research outputs
Top Co-Authors

Avatar

Alan Kenneth Burnett

University of Alabama at Birmingham

View shared research outputs
Researchain Logo
Decentralizing Knowledge